The shares of the Nasdaq-listed Regencell Bioscience skyrocketed a whopping 23,000 percent in just four months. The stock closed at $877 per share on May 30, marking a significant jump from $3.81 per share on February 3.
The early-stage bioscience company is engaged in the research, development and commercialisation of traditional Chinese medicines, which are used to treat neurocognitive disorders and degeneration. "Regencell's goal is to save and improve the lives of patients, families and caregivers and be the market leader for the best treatment of ADHD and ASD globally," the company's website reads.
Interestingly, the company is headquartered in China, a country which currently is scouting through severe trade tensions with US.
Regencell was founded in 2014 when the company's Chief Operating Officer James Chung, who was admitted as a patient for a different illness, allegedly experienced amazing healing capability in a treatment. The company's CEO Yat-Gai Au later joined him to conduct more research and develop their formula.
Regencell Bioscience has only 12 employees, reports said citing its official filings. The stock has a market capitalisation of $10 billion.Earlier this year, the company announced a forward stock split to be paid in the form of a stock bonus. "Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025," the firm said in an exchange filing.
It will be interesting to watch how the stock, which has skyrocketed over the recent months, behaves after it turns ex-date for the stock split.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.